naltrexone

This page shows the latest naltrexone news and features for those working in and with pharma, biotech and healthcare.

FDA panel backs Pfizer and Teva abuse-resistant painkillers

The panel also voted by nine votes to six in favour of approving Pfizer's Troxyca ER (oxycodone/naltrexone) for the sane indication. ... In the case of Troxyca ER, the inclusion of opioid blocker naltrexone is designed to achieve the same end result.

Latest news

Takeda files block on generic diet pill launch

The lawsuit alleges that the generic drugmaker Actavis has infringed patents on Orexigen and Takeda's new weight-loss treatment Contrave (naltrexone and bupropion).
Saxenda debuts in US with $1,000-a-month price tag

s Contrave (bupropion/naltrexone), Arena/Eisai's Belviq (lorcaserin) and Vivus' Qsymia (phentermine/topiramate), although for patients the monthly cost will fall depending on their insurance cover. .
Positive data in Saxenda diabetes prevention study

the US of three other drugs; Eisai and Arena's Belviq (lorcaserin), Vivus' Qsymia (phentermine/topiramate) and Orexigen's Contrave (naltrexone and bupropion).
CHMP thumbs up for Novo's obesity drug Saxenda

new products - Eisai and Arena's Belviq (lorcaserin), Vivus' Qsymia (phentermine/topiramate) and Orexigen's Contrave (naltrexone and bupropion) in the last couple of years in the US and other world
Orexigen’s obesity pill Mysimba set for European approval

The drug is a combination of the antidepressant bupropion and Orexigen's formulation of naltrexone, a drug designed to prevent drug dependence. ... The CHMP has recommended a marketing authorisation for Mysimba (naltrexone/bupropion) for weight